Article
Medicine, General & Internal
Amy S. Paller, Eric L. Simpson, Elaine C. Siegfried, Michael J. Cork, Andreas Wollenberg, Peter D. Arkwright, Weily Soong, Mercedes E. Gonzalez, Lynda C. Schneider, Robert Sidbury, Benjamin Lockshin, Steven Meltzer, Zhixiao Wang, Leda P. Mannent, Nikhil Amin, Yiping Sun, Elizabeth Laws, Bolanle Akinlade, Myles Dillon, Matthew P. Kosloski, Mohamed A. Kamal, Ariane Dubost-Brama, Naimish Patel, David M. Weinreich, George D. Yancopoulos, John T. O'Malley, Ashish Bansal
Summary: This study aimed to evaluate the efficacy and safety of dupilumab with low-potency topical corticosteroids in children aged 6 months to younger than 6 years with moderate-to-severe atopic dermatitis. The results showed that dupilumab significantly improved atopic dermatitis signs and symptoms versus placebo in children younger than 6 years, with well tolerated and acceptable safety profile similar to older children and adults.
Article
Medicine, General & Internal
Thomas Bieber, Eric L. Simpson, Jonathan I. Silverberg, Diamant Thaci, Carle Paul, Andrew E. Pink, Yoko Kataoka, Chia-Yu Chu, Marco DiBonaventura, Ricardo Rojo, Jeremias Antinew, Ileana Ionita, Rodney Sinclair, Seth Forman, Jacek Zdybski, Pinaki Biswas, Bimal Malhotra, Fan Zhang, Hernan Valdez
Summary: The study demonstrated that both 200 mg and 100 mg doses of abrocitinib showed significant efficacy in treating moderate-to-severe atopic dermatitis compared to placebo, with the 200 mg dose being superior to dupilumab in improving itch response. Neither dose of abrocitinib showed significant differences from dupilumab in most other key secondary endpoints at week 16.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Pierre-Francois Clot, Mohamed Kamal, Jing Sun, Christine Xu, Fangyuan Kong, Yongzhen Gu, Na Yang, WeiHong Yin, Bing Chen, Jeffrey E. Ming, Yaozong Yuan
Summary: The study demonstrates that the pharmacokinetics of Dupilumab in Chinese patients are generally comparable to non-Asian populations, with dose increase leading to proportional increases in blood drug concentrations. Adjusting the dosage based on weight is unnecessary for clinical efficacy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Dermatology
Elaine C. Siegfried, Eric L. Simpson, Michael J. Cork, Peter D. Arkwright, Lara Wine Lee, Zhen Chen, Randy Prescilla, Ashish Bansal, Noah A. Levit, Ainara Rodriguez Marco
Summary: This study evaluated the effect of dupilumab on the extent and severity of atopic dermatitis in different anatomical regions. The results showed that dupilumab treatment resulted in significant improvement in AD signs, including erythema, excoriations, infiltration/papulation, and lichenification, in all anatomical regions.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
Nali Yang, Yahui Ye, Junyi Shao, Hanwen Wu, Qiuyang Xu, Jilin Zhu, Jingjing Liu, Zhiming Li
Summary: This study aimed to describe the safety and efficacy of dupilumab in pediatric patients and examined differences of efficacy with various doses. The results showed that dupilumab treatment had significant efficacy in children aged 6 months to 11 years with moderate-to-severe atopic dermatitis, and was also safe.
Article
Medicine, General & Internal
Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P. Rice, H. Chih-ho Hong, Norito Katoh, Fernando Valenzuela, Marco DiBonaventura, Tamara A. Bratt, Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernan Valdez, Urs Kerkmann
Summary: This study compared the efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis. Results showed that abrocitinib was more effective in inducing early reductions of itch and atopic dermatitis disease signs under background topical therapy.
Article
Medicine, General & Internal
Federica Gelato, Luca Mastorino, Ekaterina Stepkina, Giovanni Cavaliere, Simone Ribero, Pietro Quaglino, Michela Ortoncelli
Summary: This retrospective study compares the efficacy of dupilumab therapy in patients with intrinsic and extrinsic atopic dermatitis (AD) and finds no significant differences in treatment outcome between the two groups, suggesting that dupilumab is equally effective regardless of IgE levels.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Dermatology
A. S. Paller, E. C. Siegfried, E. L. Simpson, M. J. Cork, B. Lockshin, M. P. Kosloski, M. A. Kamal, J. D. Davis, X. Sun, G. Pirozzi, N. M. H. Graham, A. Gadkari, L. Eckert, M. Ruddy, A. Bansal
Summary: The study evaluated the pharmacokinetics, safety, and efficacy of single-dose dupilumab in children with severe AD aged 6 months to 6 years. The results showed generally good tolerability and substantial reduction in clinical signs/symptoms of AD, with slightly better responses in older children.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Nutrition & Dietetics
Paula Danielle Santa Maria Albuquerque de Andrade, Jorgete Silva, Vanessa Carregaro, Lais Amorim Sacramento, Luciana Rodrigues Roberti, Davi Casale Aragon, Fabio Carmona, Persio Roxo-Junior
Summary: This study evaluated the clinical efficacy of a mixture of Lactobacillus and Bifidobacterium probiotics in children and adolescents with atopic dermatitis. The results showed that this probiotic mixture significantly reduced skin symptoms and the need for immunosuppressants.
FRONTIERS IN NUTRITION
(2022)
Article
Ophthalmology
Canan Asli Utine, Gavin Li, Penny Asbell, Stephen Pflugfelder, Esen Akpek
Summary: Dupilumab, the first FDA approved biologic for atopic dermatitis treatment, may cause conjunctivitis and be associated with Th1-mediated inflammation, suggesting potential adverse effects on ocular health.
Review
Dermatology
Shanthi Narla, Jonathan Silverberg, Eric L. Simpson
Summary: Atopic dermatitis is a chronic inflammatory skin disease, and dupilumab is the only approved systemic therapy for moderate-to-severe cases. Limited literature is available on treatment failure with dupilumab, and individual goals and quality of life should be considered. Possible confounding dermatoses should be ruled out.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Dermatology
Filomena Russo, Nicola Milanesi, Alessandra Cartocci, Francesco Bruzziches, Greta Tronconi, Laura Lazzeri, Angelo Massimiliano D'erme, Giovanni Bagnoni, Massimo Gola, Elisa Cinotti, Pietro Rubegni, Maria Laura Flori
Summary: This study evaluated the efficacy and tolerability of dupilumab in treating elderly patients with severe AD, showing significant improvements in EASI, Pruritus NRS, and DLQI after 4 months of therapy. The majority of patients experienced improvement, with a lower percentage of conjunctivitis reported compared to studies on adults. Larger, controlled case studies are needed to determine potential differences in dosage or frequency of administration for elderly patients.
Article
Immunology
Lishan Zhang, Xueyi Wen, Yibo Hou, Yongshi Yang, Wei Song, Yueping Zeng, Jinlyu Sun
Summary: The study found significant changes in serum metabolites of patients with atopic dermatitis after 16 weeks of dupilumab treatment, with differential metabolites and related metabolic pathways providing clues for understanding the effects of dupilumab on patient metabolism.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Dermatology
Shi Yun Chia, Lynette Wei Yi Wee, Mark Jean Aan Koh
Summary: This study retrospectively analyzed the efficacy and safety of dupilumab in Asian children and adolescents with moderate-to-severe AD. The results showed that dupilumab is an effective and safe treatment option for these patients.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Mariko Ogawa-Momohara, Yoshinao Muro, Chiaki Murase, Tomoki Taki, Kana Tanahashi, Yuta Yamashita, Haruka Koizumi, Ryo Fukaura, Takuya Takeichi, Masashi Akiyama
Summary: This small-scale prospective study investigated the changes in antigen-specific IgG4 (sIgG4) during long-term dupilumab treatment in patients with atopic dermatitis. Despite the reported inhibitory effect of dupilumab on B-cell maturation, the increase in sIgG4 during the treatment suggests a potential indirect improvement of allergies in predisposed individuals. This study presents the possibility of a new therapeutic effect of long-term dupilumab use.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
